Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Completes Acquisition of Dako

NEW YORK (GenomeWeb News) – Agilent Technologies today said that it has completed the acquisition of Dako for $2.2 billion in cash.

Agilent signed the deal to acquire the Danish cancer diagnostics firm last month and said at the time that it would fund the acquisition entirely with its off-shore cash. The acquisition provides Agilent with Dako's immunohistochemistry products and a growing companion diagnostics business.

Didier Hirsch, chief financial officer for Agilent, has said that Dako is expected to generate $373 million in revenues in fiscal 2013 with $68 million operating profit and an operating margin of 18 percent.

As a result of the acquisition, Agilent said that it will now add a fourth business reporting segment, the Diagnostics and Genomics Group. Its three other reporting segments are Life Sciences, Chemical Analysis, and Electronic Measurement.

The new segment consists of Dako, led by Dako CEO Lars Holmkvist, and the Genomics Solutions Division, led by Bob Schueren, VP and GM of Agilent's genomics group. The new segment will report directly to Agilent President and CEO Bill Sullivan.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.